The size of the Global Non-Insulin Diabetes Therapies Market revenue is expected to be growing at a CAGR of 5.6% from 2021 to 2026. The size of the market is estimated to grow USD 21.36 billion by 2026 from USD 16.26 billion in 2021.
Non-Insulin Diabetes Therapeutics are administered orally and are prescribed to the person when the body glucose levels are elevated and cannot be controlled by Diet and Exercise.
The major factors driving the growth of the market is the increase in the number of people affected by Diabetes Type 2. The figure for people who have diabetes is expected to rise to 642 million by 2040. The engagement of companies to find medicines with fewer side effects has contributed a lot to the growth of the market. Non-Insulin drugs, when injected into the body, helps the liver to produce Insulin. The Insulin market dominated previously, but the type of the Non-Insulin drug will soon be at the same level as Insulin Type drugs. The change in lifestyle and food habits is the cause of diabetes, and thus, they will push forward market growth.
The primary challenge for this market is to produce drugs that have fewer side effects and are more effective than the currently used drugs. The benefits of these drugs are still unknown to many, so less awareness is also a challenge. The availability of these drugs to all people classes is also a big challenge as diabetes is a common disease. The general awareness about the functioning and uses of drugs is not known to many, making people more aware is another challenge for this market. The market leaders in this segment are based in few regions only, and thus the market penetration of the drugs is not so much, which results in low sales and less awareness. The government initiatives about increasing people’s attention are not in huge numbers and thus restrict the growth of the market.
Impact of COVID-19 on the global non-insulin diabetes therapies market
The COVID-19 pandemic is a serious situation right now, and the increasing number of new positive cases is a cause for concern for the whole world. The coronavirus and its effects on the body are being studied by scientists and pharmaceutical companies worldwide. The coronavirus is found to affect severely people who have heart problems or are suffering from diabetes. Thus, the non-insulin drug market is expected to grow during the pandemic as people need to treat heir diabetes so that the coronavirus does not become a deadly catalyst severely affecting the body. The lockdown prevented the supply and demand from being at the same level, and thus this gap between supply and demand is still needed to be filled. The lockdown also affected the movement of people, and the patients who have diabetes were not able to see their doctor, thus hampering the growth of the market.
Market Size Available
2020 to 2026
2021 to 2026
By Drug Type and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
Market Leaders Profiled
Tobira (New Jersey), Eli Lilly and Sumitomo Dainippon Pharma (Japan), Novo Nordisk (Denmark), Takeda (Japan), Sanofi (China), Mannkind (California), Bristol-Myers Squibb (New York), AstraZeneca (U.K), Boehringer Ingelheim (Germany) and Bayer (Germany).
This research report on the Global Non-Insulin Diabetes Therapies Market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2026.
Non-Insulin Diabetes Therapies Market – By Drug Type:
The SGLT-2 inhibitors segment is expected to witness robust growth during the forecast period based on the drug type. The main reason contributing to growth is the minimum side effects of these drugs. These drug types are also very efficient as monotherapy or combination therapy. More detailed research is being carried out to find a new and efficient type of molecule. During the forecast period, Novartis and Ionis Pharmaceuticals products are the significant pipelines SGLT 2 inhibitors are in the process of a clinical study and is expected to launch during the forecast period.
Biguanides drug type is currently in a shallow position in terms of market share but is expected to grow at a reasonable rate during the forecast period. These drugs work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for diabetes treatment. Thus set up of new companies and an effective supply chain will ensure the growth of this sub-segment.
Non-Insulin Diabetes Therapies Market – By Region:
Geographically, North America had the largest market share in 2020 and is expected to grow with a healthy rate during the forecast period. The increasing prevalence of diabetes is the primary factor supporting the growth rate. The other reasons propelling the market are many ongoing clinical trials and the availability of improved treatment options and health care infrastructure. The presence of global players is going to affect the market positively.
Europe had the second largest market share in 2019 and is expected to grow with a healthy future rate. The increasing diabetes cases due to the prevalence of unhealthy lifestyles and the rising quality of healthcare facilities will support the positive growth of this region.
The Asia Pacific market is expected to grow at the fastest rate among other regions. China has more diabetic patients than any other country globally, surpassing India, in the recent past. In India, about 62 million people are facing problems related to Diabetics. About 80 thousand deaths are expected to occur in America because of diabetes, and recent studies show us that around 1.4 million people have been diagnosed and treated for Type-2 Diabetes. The market is expected to increase exponentially in the coming years due to the rise in the number of people facing diabetic problems.
KEY MARKET PLAYERS:
Some of the key competitors participating in the Global Non-Insulin Diabetes Therapies Market profiled in this report are Tobira, Eli Lilly, and Sumitomo Dainippon Pharma, Novo Nordisk, Takeda, Sanofi, Mannkind, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Bayer.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.3 Amylin Agonists
5.1.4 GLP-1 Agonists & Analogs
5.1.6 Glinides & Meglinitides
5.1.7 Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors
5.1.8 Thiazolidinediones (or Glitazones or TZDs
5.1.9 Alpha-Glucosidase Inhibitors
5.1.10 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
5.1.11 Y-o-Y Growth Analysis, By Drug Type
5.1.12 Market Attractiveness Analysis, By Drug Type
5.1.13 Market Share Analysis, By Drug Type
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Drug Type
6.1.4 Market Attractiveness Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Drug Type
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Drug Product
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novo Nordisk
8.4 Eli Lilly Sumitomo Dainippon Pharma
8.8 Bristol Myers Squibb
8.10 Boehringer Ingelheim
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures